Recent advancements in therapies show promising results for liver disease, with a new treatment resolving NASH in 77% of patients. Additionally, innovative gut hormone therapies are leading to significant weight loss, rivaling bariatric surgery outcomes. However, concerns about drug pricing and accessibility remain critical, especially with a substantial portion of patients unable to afford their prescriptions.
